Sign In

Login

Password

Forgot Password ? Sign Up

CD19 (Czech Wikipedia)

Analysis of information sources in references of the Wikipedia article "CD19" in Czech language version.

Last modified:

Ref.Un. Ref.Website
Global rank Czech rank
88doi.org
2nd place
4th place
66worldcat.org
4th place
2nd place
44nih.gov
5th place
8th place
22archive.org
6th place
5th place
22annualreviews.org
2,959th place
1,487th place
11biomedcentral.com
2,731st place
549th place
11embopress.org
low place
low place
11jci.org
low place
7,634th place
11nejm.org
2,717th place
1,741st place
11springer.com
182nd place
137th place
11elsevier.com
365th place
150th place

annualreviews.org (Global: 2,959th place; Czech: 1,487th place)

archive.org (Global: 6th place; Czech: 5th place)

biomedcentral.com (Global: 2,731st place; Czech: 549th place)

ehoonline.biomedcentral.com

doi.org (Global: 2nd place; Czech: 4th place)

  • HARWOOD, Naomi E.; BATISTA, Facundo D. Early Events in B Cell Activation. Annual Review of Immunology. 2010-03-01, roč. 28, čís. 1, s. 185–210. Dostupné online [cit. 2024-02-16]. ISSN 0732-0582. doi:10.1146/annurev-immunol-030409-101216. (anglicky)
  • FEARON, Douglas T.; CARROLL, Michael C.; CARROLL, Michael C. Regulation of B Lymphocyte Responses to Foreign and Self-Antigens by the CD19/CD21 Complex. Annual Review of Immunology. 2000-04, roč. 18, čís. 1, s. 393–422. Dostupné online [cit. 2024-02-16]. ISSN 0732-0582. doi:10.1146/annurev.immunol.18.1.393. (anglicky)
  • WANG, Kemeng; WEI, Guoqing; LIU, Delong. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology. 2012-12, roč. 1, čís. 1. Dostupné online [cit. 2024-02-16]. ISSN 2162-3619. doi:10.1186/2162-3619-1-36. PMID 23210908. (anglicky)
  • NUTT, S. L. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. The EMBO Journal. 1998-04-15, roč. 17, čís. 8, s. 2319–2333. Dostupné online [cit. 2024-02-16]. doi:10.1093/emboj/17.8.2319. PMID 9545244.
  • CHUNG, Elaine Y.; PSATHAS, James N.; YU, Duonan. CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis. Journal of Clinical Investigation. 2012-06-01, roč. 122, čís. 6, s. 2257–2266. Dostupné online [cit. 2024-02-16]. ISSN 0021-9738. doi:10.1172/JCI45851. PMID 22546857. (anglicky)
  • VAN ZELM, Menno C.; REISLI, Ismail; VAN DER BURG, Mirjam. An Antibody-Deficiency Syndrome Due to Mutations in the CD19 Gene. New England Journal of Medicine. 2006-05-04, roč. 354, čís. 18, s. 1901–1912. Dostupné online [cit. 2024-02-16]. ISSN 0028-4793. doi:10.1056/NEJMoa051568. (anglicky)
  • ZINZANI, Pier Luigi; MINOTTI, Giorgio. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology. 2022-01, roč. 148, čís. 1, s. 177–190. Dostupné online [cit. 2024-02-16]. ISSN 0171-5216. doi:10.1007/s00432-021-03833-x. PMID 34741682. (anglicky)
  • ABRAMSON, Jeremy S. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Transfusion Medicine Reviews. 2020-01, roč. 34, čís. 1, s. 29–33. Dostupné online [cit. 2024-02-16]. doi:10.1016/j.tmrv.2019.08.003. (anglicky)

elsevier.com (Global: 365th place; Czech: 150th place)

linkinghub.elsevier.com

  • ABRAMSON, Jeremy S. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma. Transfusion Medicine Reviews. 2020-01, roč. 34, čís. 1, s. 29–33. Dostupné online [cit. 2024-02-16]. doi:10.1016/j.tmrv.2019.08.003. (anglicky)

embopress.org (Global: low place; Czech: low place)

emboj.embopress.org

  • NUTT, S. L. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. The EMBO Journal. 1998-04-15, roč. 17, čís. 8, s. 2319–2333. Dostupné online [cit. 2024-02-16]. doi:10.1093/emboj/17.8.2319. PMID 9545244.

jci.org (Global: low place; Czech: 7,634th place)

  • CHUNG, Elaine Y.; PSATHAS, James N.; YU, Duonan. CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis. Journal of Clinical Investigation. 2012-06-01, roč. 122, čís. 6, s. 2257–2266. Dostupné online [cit. 2024-02-16]. ISSN 0021-9738. doi:10.1172/JCI45851. PMID 22546857. (anglicky)

nejm.org (Global: 2,717th place; Czech: 1,741st place)

  • VAN ZELM, Menno C.; REISLI, Ismail; VAN DER BURG, Mirjam. An Antibody-Deficiency Syndrome Due to Mutations in the CD19 Gene. New England Journal of Medicine. 2006-05-04, roč. 354, čís. 18, s. 1901–1912. Dostupné online [cit. 2024-02-16]. ISSN 0028-4793. doi:10.1056/NEJMoa051568. (anglicky)

nih.gov (Global: 5th place; Czech: 8th place)

ncbi.nlm.nih.gov

  • WANG, Kemeng; WEI, Guoqing; LIU, Delong. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Experimental Hematology & Oncology. 2012-12, roč. 1, čís. 1. Dostupné online [cit. 2024-02-16]. ISSN 2162-3619. doi:10.1186/2162-3619-1-36. PMID 23210908. (anglicky)
  • NUTT, S. L. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. The EMBO Journal. 1998-04-15, roč. 17, čís. 8, s. 2319–2333. Dostupné online [cit. 2024-02-16]. doi:10.1093/emboj/17.8.2319. PMID 9545244.
  • CHUNG, Elaine Y.; PSATHAS, James N.; YU, Duonan. CD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesis. Journal of Clinical Investigation. 2012-06-01, roč. 122, čís. 6, s. 2257–2266. Dostupné online [cit. 2024-02-16]. ISSN 0021-9738. doi:10.1172/JCI45851. PMID 22546857. (anglicky)
  • ZINZANI, Pier Luigi; MINOTTI, Giorgio. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology. 2022-01, roč. 148, čís. 1, s. 177–190. Dostupné online [cit. 2024-02-16]. ISSN 0171-5216. doi:10.1007/s00432-021-03833-x. PMID 34741682. (anglicky)

springer.com (Global: 182nd place; Czech: 137th place)

link.springer.com

  • ZINZANI, Pier Luigi; MINOTTI, Giorgio. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. Journal of Cancer Research and Clinical Oncology. 2022-01, roč. 148, čís. 1, s. 177–190. Dostupné online [cit. 2024-02-16]. ISSN 0171-5216. doi:10.1007/s00432-021-03833-x. PMID 34741682. (anglicky)

worldcat.org (Global: 4th place; Czech: 2nd place)